Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

green-chart-shutter copy

Government

News

Broad U.S. Equity ETFs

ETFs

FORM

FTAI

FWRD

HUMA

IONQ

LOVE

SITM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Trump&#39;s tariff delay caused the small-cap stocks in iShares Russell 2000 ETF to rise significantly. Semiconductor components were also top performers.

Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000

blur-1853262

Humacyte shares are trading lower by 29% during Wednesday&#39;s session. The company priced a $50 million public offering.

Why Humacyte (HUMA) Stock Is Falling Sharply

Super Micro Computer, Bakkt Holdings, MARA Holdings, Microstrategy, And Tesla Inc: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Markets

Movers

Trading Ideas

CHWY

NYXH

ORKA

PPTA

RAPP

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Humacyte Inc

HUMAN PHEROMONE SCIENCE by Human Pheromone Sciences, Inc.

Human - United States Dollar

HUMAN HOLDINGS CO LTD by Human Holdings Co., Ltd.

Human Holdings Co Ltd

HUMAN UNITEC INTL INC by Human Unitec International, Inc.

Human Unitec International Inc

Humana Inc

Humanigen Inc

Humankind US Stock ETF

Humanscape

Humatech Inc

Press Releases

General

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Health Care

Legal

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Financing

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Earnings

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Anika Therapeutics

Annexon

Candel Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Genfit

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Regulus Therapeutics

Solid Biosciences

Acelyrin

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

D. Boral Capital

HC Wainwright & Co.

EF Hutton

TD Cowen

BTIG

Comments

Humacyte

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell